Discover and read the best of Twitter Threads about #NeulandLabs
Most recents (8)
Mega thread on Technical Stage Analysis and my learnings based on Stan Weinstein's book.
Today we'll cover
1. Stage Analysis
2. Technical Rules for Buy and Sell
3. Safest Point of Entry and Exit
4. Study 10 🇮🇳 Stock Charts (Large/Mid/Smallcap)
1/n
Today we'll cover
1. Stage Analysis
2. Technical Rules for Buy and Sell
3. Safest Point of Entry and Exit
4. Study 10 🇮🇳 Stock Charts (Large/Mid/Smallcap)
1/n
1. Stage Analysis
As per Stan Weinstein, each stock can be classified into 1 of 4 different stages.
Stage 1 - Basing Area
Stock trades in a range around 30W SMA over a long period of time with low volume. Both buyers & sellers move in equilibrium.
Example: #MusicBroadcast
2/n
As per Stan Weinstein, each stock can be classified into 1 of 4 different stages.
Stage 1 - Basing Area
Stock trades in a range around 30W SMA over a long period of time with low volume. Both buyers & sellers move in equilibrium.
Example: #MusicBroadcast
2/n
1. Stage Analysis
Stage 2 - Advancing Phase
This phase is characterized by a sharp spike in volumes, breaking out of key resistance and sharply rising stock price over a period of time (many months or years) without breaking the key moving average.
Example: #FineOrganics
3/n
Stage 2 - Advancing Phase
This phase is characterized by a sharp spike in volumes, breaking out of key resistance and sharply rising stock price over a period of time (many months or years) without breaking the key moving average.
Example: #FineOrganics
3/n
#Diamines & Chemicals
Market Cap : 414 Cr
How I Identified ?
1. Diamines and chemicals is into manufacturing of #piperzaine and #ethylenediamines
They have > 40% market of piperazine which goes into ciprofloxacin (API)
#aartiindustries & #neulandlabs manufacture ciprofloxacin
Market Cap : 414 Cr
How I Identified ?
1. Diamines and chemicals is into manufacturing of #piperzaine and #ethylenediamines
They have > 40% market of piperazine which goes into ciprofloxacin (API)
#aartiindustries & #neulandlabs manufacture ciprofloxacin
2. R&D Expenses increasing year on year
3. Investing 14.5 Cr for Pilot plant for newer downstream Products
#NeulandLabs Q3 FY22 concall highlights 💊💊
Like & retweet for better reach !
1. Revenue for the quarter is ₹238.4 Cr (2.9% decline YoY). EBITDA for the quarter was ₹34.2 Cr (26.8% decline YoY) with an EBITDA margin of 14.3%.
Like & retweet for better reach !
1. Revenue for the quarter is ₹238.4 Cr (2.9% decline YoY). EBITDA for the quarter was ₹34.2 Cr (26.8% decline YoY) with an EBITDA margin of 14.3%.
2. They are facing supply chain issues due to raw material volatility and high logistics cost. They also benefited in the last few quarters due to raw material hedging for key ingredients, but those contracts expired in Q2 which caused a decline in margins.
They are holding higher inventory in case of possible future disruptions.
3. Currently profitability is low due to costs associated with commercialization on Unit 3. They expect more volumes from Unit 3 in the coming quarters.
3. Currently profitability is low due to costs associated with commercialization on Unit 3. They expect more volumes from Unit 3 in the coming quarters.
A thread🧵 on so called market traps of transitionary performing stocks which leads to retail getting stuck. Doing as lot of tweets floating on such stocks.
Will take example of one of such stock with my own twitter history though I never presented in public #Neulandlabs
Will take example of one of such stock with my own twitter history though I never presented in public #Neulandlabs
1. If you think, every performing stock will become an Asian paints, you are in for disaster. 99% of businesses are cyclic, only quantum differs. So, either do not overpay or if overpaying a bit and have confidence in the business, then,
hold for long (15-20% of companies still in long run generate 15%+ CAGR). One should know his time frame, expectation, price he or she is paying and what kind of investor class he belongs to. This is how story usually starts and ends:
🌟Looking forward to #MuhuratTrading?
🙌Check out this thread to see what #Trinkerr Experts chose as their top #DIWALIPICKS! ✨
#StockMarket #stocks
🙌Check out this thread to see what #Trinkerr Experts chose as their top #DIWALIPICKS! ✨
#StockMarket #stocks
✨@MoneyMystery's #DIWALIPICKS for #MuhuratTrading🎁
🌟#InoxLeisure
💫Checkout his complete #Trinkerr portfolio: trin.kr/RwuX
🌟#InoxLeisure
💫Checkout his complete #Trinkerr portfolio: trin.kr/RwuX
✨ @MarketScientist's #DIWALIPICKS for #MuhuratTrading🎁
🌟#ACE
🌟#Borosil
🌟#JBMGroup
🌟#GNFC
🌟#westlife
🌟#AssociatedBreweries
💫Checkout his complete #Trinkerr portfolio: trin.kr/pwiC
🌟#ACE
🌟#Borosil
🌟#JBMGroup
🌟#GNFC
🌟#westlife
🌟#AssociatedBreweries
💫Checkout his complete #Trinkerr portfolio: trin.kr/pwiC
1 new chart everyday, it could be from any space ~ equities / commodities / crypto / forex / bonds , etc
Will try to do it daily 🙏💪
Here's the first one 👇
SBI vs BankNifty
Ratio chart has given monthly breakout implying SBI could outperform BN in coming months.
#PB365
Will try to do it daily 🙏💪
Here's the first one 👇
SBI vs BankNifty
Ratio chart has given monthly breakout implying SBI could outperform BN in coming months.
#PB365
Took 2nd Entry in #NEULANDLABS @ 892.
Booked too @ 995. #Climactic + #BRN
Still holding 1st position @ 855
Booked too @ 995. #Climactic + #BRN
Still holding 1st position @ 855
Sold another 25% @ 1097. Huge move!
Final Exit #NEULAND @ 1025. Needs time to digest the accumulated supply.
#NEULANDLABS
- 30years old co. engaged in R&D, mfg & marketing of bulk drugs, intermediates and custom synthesis of APIs (CMS)
- Cleared 15 USFDA audit without failure.
- 93% of revenues through regulated markets
-3 Mfg Sites Total capacity - 729 Kilo Ltr
- 30years old co. engaged in R&D, mfg & marketing of bulk drugs, intermediates and custom synthesis of APIs (CMS)
- Cleared 15 USFDA audit without failure.
- 93% of revenues through regulated markets
-3 Mfg Sites Total capacity - 729 Kilo Ltr
-Unit 3 (197KL) was acquired 2017 for about Rs.100cr & it was largely funded through debt.
-Unit 3 still hasn't contributed to the rev. & it is expected to contribute in FY21
-Business is divided into 2 main segments
1.GENERIC DRUG SUBSTANCE
2.Custom Manufacturing Solutions (CMS
-Unit 3 still hasn't contributed to the rev. & it is expected to contribute in FY21
-Business is divided into 2 main segments
1.GENERIC DRUG SUBSTANCE
2.Custom Manufacturing Solutions (CMS
1.GENERIC DRUG SUBSTANCE (GDS) contributed 68% to FY20 Topline
is further divided into 2 verticals.
1.Prime Api's (High Vol. Low Value)
2.Niche Api's(Low vol. high Value)
is further divided into 2 verticals.
1.Prime Api's (High Vol. Low Value)
2.Niche Api's(Low vol. high Value)
